Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
about
Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's DiseaseDrug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumabGenetics of rheumatoid arthritis contributes to biology and drug discoveryBrain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum diffIncrease of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis.Tocilizumab-Induced Acute Liver Injury in Adult Onset Still's DiseaseReduction of Serum ADAM17 Level Accompanied with Decreased Cytokines after Abatacept Therapy in Patients with Rheumatoid ArthritisHead-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registryManagement of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerationsAPLAR rheumatoid arthritis treatment recommendations.The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesSerum biomarkers of clinical and cytologic response in dogs with idiopathic immune-mediated polyarthropathy.Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials.Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritisTocilizumab in the treatment of rheumatoid arthritis and beyond.Targeting interleukin-6 in rheumatoid arthritis.Aryl hydrocarbon receptor and experimental autoimmune arthritis.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure.Adalimumab in the treatment of rheumatoid arthritis.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment.Adverse reactions to biologic agents and their medical management.IL-6 biology: implications for clinical targeting in rheumatic disease.IL-6 blockade in chronic inflammatory diseases.Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis.Alarmin' Immunologists: IL-33 as a Putative Target for Modulating T Cell-Dependent ResponsesTreatment of adult-onset still's disease: up to date.Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.Ex vivo all-trans retinoic acid modulates NO production and regulates IL-6 effect during rheumatoid arthritis: a study in Algerian patients.Confirmation of effectiveness of tocilizumab by ultrasonography and magnetic resonance imaging in biologic agent-naïve early-stage rheumatoid arthritis patients.Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.P03-024 – Early onset IBD treated by tocilizumab.Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.The balance between Treg and TH17 cells: CD11b and interleukin-6.The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.
P2860
Q26772331-0E419214-89C6-4FF4-B4E1-FCF5ABB68250Q27023091-0FE2E6EE-4C7D-4D28-820C-14A5D1F90497Q29417000-D094056E-CBE8-40FA-82FB-82EB3DD157BFQ30416813-6FFD2B1B-55AC-4FB3-AE30-24F5E838A216Q33689977-928000CB-6BD1-49D9-9179-C8E33AC6F1BDQ34399037-8D4AE2B8-6D2F-4E75-B3F7-DA1779E25F45Q34903101-9CAFABE6-0E1B-490F-A1D6-845B0049F53EQ35258244-ACB13F0D-61FC-4097-BAE0-0CF4B64C9399Q35618458-9E9401B9-B00F-48B0-B2BB-9CE94E2C559FQ35762912-CB83E63C-5657-4BE9-9738-3F3F50DB5897Q35764862-7A9ACC1F-6DB8-4A9B-BD79-1AD79ABCA5C1Q36183803-C1ABA75B-0621-480A-9690-7717F046EFE7Q36975028-03046737-3C08-4DD6-BC47-F39BD2B39A2BQ37278384-2840EF4E-DEEC-44E4-B1A4-E425FEF1D0FAQ37433269-0E196FB7-4067-4F04-ACC3-C4048316E5DFQ37682799-2A131F83-F440-4B7E-B0B3-EB8855DEE339Q38086137-E5E022CA-8CD9-4E04-A819-13B3CA85C429Q38132000-EF584594-2962-425F-96F5-DCA836C4E28FQ38164315-6FDA513F-DDC1-4B3B-89BE-40BD1088FA25Q38183314-57E082ED-2F6D-4C39-878F-EA5DBEC8A231Q38192659-2F58040D-ECBC-44E2-B7FD-2AA96305440AQ38201788-028369BD-6DFB-4CD1-9664-6DBAA7F067B7Q38203622-C87967B6-E246-44FD-A21A-8CA397C642B0Q38207142-B5E6E751-DD9B-4A84-863C-8F58C84A99B4Q38210794-4159D156-B0A0-42C8-88B9-EDFC8D548576Q38238948-4A983695-C3DC-4A10-9063-25CFD32D0089Q38241232-549E3629-C064-4015-92BE-298A43C21785Q38261783-F656FBCA-20B9-43FF-AB52-33B9D103AC0CQ38285827-02F0A493-22B1-4F80-9E40-4A8CBEC56C01Q38287819-4EAE4CE8-A847-44AB-8097-EAC5F0441DBDQ38530106-25FD6B72-C5AF-4A73-8B8E-5A70AEB94200Q38679486-2E5CF9E1-C0B6-4D7D-9517-DD2D68BBAE6EQ38805575-EC91E642-E0A7-4AEC-B4DB-8A97B58CC83DQ38880593-2C3A77B3-C68E-4980-8E53-15E7B3D77B3CQ43446284-38661E41-8DC3-433F-B3E3-CD5BEB2977A6Q45329549-1C69DDDC-2C0C-4F9A-92B1-6487DD60EE87Q46049396-6E55883E-4552-4C88-833A-B0E85DBB3E50Q50589517-B43A238E-4F27-4AA1-8752-72870C335E2FQ51067514-0B41C0A3-6C70-4791-97EA-BC48BBF11AF9Q52839665-43746E10-BEA4-40B1-A063-C9A54C8E5BF1
P2860
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Consensus statement on blockin ...... other inflammatory conditions.
@ast
Consensus statement on blockin ...... other inflammatory conditions.
@en
Consensus statement on blockin ...... other inflammatory conditions.
@en-gb
type
label
Consensus statement on blockin ...... other inflammatory conditions.
@ast
Consensus statement on blockin ...... other inflammatory conditions.
@en
Consensus statement on blockin ...... other inflammatory conditions.
@en-gb
prefLabel
Consensus statement on blockin ...... other inflammatory conditions.
@ast
Consensus statement on blockin ...... other inflammatory conditions.
@en
Consensus statement on blockin ...... other inflammatory conditions.
@en-gb
P2093
P2860
P50
P1476
Consensus statement on blockin ...... other inflammatory conditions.
@en
P2093
Allan Gibofsky
Andrea Rubbert-Roth
Angel Lanas
Bernard Combe
Clifton O Bingham
Ernest H Choy
Ferdinand C Breedveld
Juan Jesus Gomez-Reino
Kevin L Winthrop
Maarten de Wit
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-202469
P407
P50
P577
2012-11-21T00:00:00Z
2013-04-01T00:00:00Z
P5875
P6179
1042839524